Hervolution Therapeutics
PrivateLast Round
Series A
Dec 19, 2024
Total Funding Raised
$28.27M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Hervolution Therapeutics operates in Healthcare & Life Sciences and is based in Copenhagen. Its latest recorded funding round was a Series A round in December 2024.
Hervolution Therapeutics is a biotechnology company that develops novel immunotherapies targeting human endogenous retroviruses (HERVs) to treat cancer, metabolic diseases, and aging-related conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hervolution Therapeutics Comparables
Compare Hervolution Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ErVimmune | 87% | |
| Enara Bio | 78% | |
| Epitopea | 77% |
For institutional investors. Book with your work email.
Hervolution Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 19, 2024 | ||||
| Seed | Jun 27, 2023 | ||||
| Seed | May 24, 2023 | ||||
| Grant | Oct 15, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Hervolution Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, Seed, Series A |
| The Export and Investment Fund of Denmark | Seed |
| BioInnovation Institute | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 7815% MoM, from 20 to 1.6K.
- Apr 27, 2026
Grew 17% QoQ, from 30 to 35 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 12, 2026
Hervolution Aps is developing immunotherapies targeting ancient viral sequences implicated in cancer and metabolic disease through a proprietary cellular-senescence platform, with IPT-001 as its lead development program in Denmark.
- hiresNov 12, 2026
Hervolution Aps appoints Professor Jens Juul Holst, co-discoverer of GLP-1, to its Scientific Advisory Board in Denmark and New York on Nov 12th '26.
- hiresNov 12, 2026
On Nov 12th '26 in Denmark, Hervolution Aps appoints Professor Jens Juul Holst to its Scientific Advisory Board, strengthening the scientific support for its IPT-001 immunotherapy program.
For institutional investors. Book with your work email.
Hervolution Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hervolution Therapeutics's valuation, stock price, and market status.
Is Hervolution Therapeutics a public or private company?
Hervolution Therapeutics is a private company.
What is the current stock price of Hervolution Therapeutics?
Hervolution Therapeutics is a private company, so its shares have no public market price. Caplight tracks Hervolution Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hervolution Therapeutics worth (valuation)?
Valuation information for Hervolution Therapeutics is not publicly available.
Can I buy Hervolution Therapeutics stock?
Hervolution Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hervolution Therapeutics's last funding round?
Hervolution Therapeutics's most recent funding round was Series A on December 19, 2024.
Who are the main investors in Hervolution Therapeutics?
Key investors in Hervolution Therapeutics include European Innovation Council Fund.
Will Hervolution Therapeutics IPO soon?
No public IPO plans have been announced for Hervolution Therapeutics.
How can I track Hervolution Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Hervolution Therapeutics's shares on secondary markets.